Muvalaplin

TargetMol
Product Code: TAR-T77695
Supplier: TargetMol
CodeSizePrice
TAR-T77695-1mg1mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T77695-5mg5mg£401.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T77695-10mg10mg£550.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T77695-25mg25mg£854.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T77695-50mg50mg£1,131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T77695-100mg100mg£1,492.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
Muvalaplin is an orally active lipoprotein (a) Lp(a) reagent that inhibits Lp(a) formation by blocking apo(a)-apo B100 interactions.
CAS:
2565656-70-2
Molecular Weight:
710.9
Purity:
0.98
SMILES:
[C@@H](CC1=CC(CN(CC2=CC(C[C@H](C(O)=O)[C@]3(CCNC3)[H])=CC=C2)CC4=CC(C[C@H](C(O)=O)[C@]5(CCNC5)[H])=CC=C4)=CC=C1)(C(O)=O)[C@]6(CCNC6)[H]

References

Nicholls SJ, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA. 2023 Sep 19;330(11):1042-1053. Bhatia HS, et al. Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies. J Clin Med. 2022 Oct 13;11(20):6040.